Compass Pathways (NASDAQ:CMPS) Sets New 12-Month High – Should You Buy?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $15.87 and last traded at $15.17, with a volume of 7718228 shares traded. The stock had previously closed at $14.04.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada reduced their price objective on shares of Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. B. Riley Financial boosted their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. BTIG Research boosted their price target on Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Stock Performance

The company’s 50-day moving average price is $13.09 and its two-hundred day moving average price is $10.50. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -3.28 and a beta of 2.54. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). On average, equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Toronto Dominion Bank lifted its stake in Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after buying an additional 1,529,013 shares during the period. Nantahala Capital Management LLC boosted its holdings in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $6,926,000. Orbimed Advisors LLC acquired a new stake in shares of Compass Pathways during the 1st quarter worth approximately $6,363,000. Finally, Siren L.L.C. bought a new stake in shares of Compass Pathways in the 4th quarter valued at $6,900,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.